Federal Circuit Upholds CorMedix Patent Win Over Nexus in Minocin® Case

Event summary

  • Federal Circuit affirmed a 2023 district court ruling that Nexus Pharmaceuticals' generic minocycline product infringes CorMedix's MINOCIN® patents.
  • The court rejected Nexus' invalidity challenge and upheld a permanent injunction blocking Nexus from marketing its generic product before patent expiration.
  • MINOCIN® is an FDA Orange Book-listed intravenous minocycline antibiotic used in hospital settings for serious infections.
  • CorMedix's subsidiary Melinta Therapeutics was the plaintiff in the original lawsuit.

The big picture

The Federal Circuit's decision reinforces the value of CorMedix's intellectual property in the intravenous minocycline market, a segment critical for treating drug-resistant infections in hospitals. This victory comes at a time when biopharmaceutical companies are increasingly relying on patent litigation to protect their innovative formulations against generic competitors. The ruling may also set a precedent for similar cases involving reformulated antibiotics, impacting broader industry dynamics around pharmaceutical innovation and market exclusivity.

What we're watching

Market Exclusivity
How long CorMedix can maintain its market position before patent expiration and potential generic competition.
Revenue Impact
Whether the legal victory will translate into sustained revenue growth for MINOCIN® in hospital settings.
IP Strategy
The pace at which CorMedix will defend or expand its intellectual property portfolio in other therapeutic areas.